H
Heimen Schraffordt Koops
Researcher at University of Groningen
Publications - 77
Citations - 3850
Heimen Schraffordt Koops is an academic researcher from University of Groningen. The author has contributed to research in topics: Germ cell tumors & Melphalan. The author has an hindex of 34, co-authored 77 publications receiving 3798 citations. Previous affiliations of Heimen Schraffordt Koops include University Medical Center Groningen.
Papers
More filters
Journal ArticleDOI
Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
Alexander M.M. Eggermont,Heimen Schraffordt Koops,Joseph M. Klausner,Bin B. R. Kroon,Peter M. Schlag,Danielle Liénard,Albertus N. van Geel,Harald J. Hoekstra,Isaac Meller,Omgo E. Nieweg,Christoph Kettelhack,Gur Ben-Ari,Jean Claude Pector,Ferdy Lejeune +13 more
TL;DR: The ILP with TNF + melphalan can be performed safely in many centers and is an effective induction treatment with a high response rate that can achieve limb salvage in patients with locally advanced extremity soft tissue sarcoma.
Journal ArticleDOI
Detection of unknown occult primary tumors using positron emission tomography
Annemieke C. Kole,Omgo E. Nieweg M.D.,Omgo E. Nieweg M.D.,Jan Pruim,Harald J. Hoekstra,Heimen Schraffordt Koops,J.L.N. Roodenburg,Willem Vaalburg,Albert Vermey +8 more
TL;DR: The potential of positron emission tomography with 18F‐fluoro‐2‐deoxy‐D‐glucose (FDG) to detect primary tumors after unsuccessful conventional diagnostic workup was assessed in patients with metastatic disease from an unknown primary tumor.
Journal ArticleDOI
Prophylactic isolated limb perfusion for localized, high-risk limb melanoma : Results of a multicenter randomized phase III trial
Heimen Schraffordt Koops,M. Vaglini,S. Suciu,Bin B. R. Kroon,J. F. Thompson,J. Góhl,A. M. M. Eggermont,F. Di Filippo,E. T. Krementz,D. Ruiter,F. J. Lejeune +10 more
TL;DR: Prophylactic ILP with melphalan cannot be recommended as an adjunct to standard surgery in high-risk primary limb melanoma.
Journal ArticleDOI
Frozen Section Investigation of the Sentinel Node in Malignant Melanoma and Breast Cancer
Pieter J. Tanis,Rob P. A. Boom,Heimen Schraffordt Koops,I. F. Faneyte,Johannes L. Peterse,Omgo E. Nieweg,Emiel J. Th. Rutgers,Anton T. M. G. Tiebosch,Bin B. R. Kroon +8 more
TL;DR: In this paper, the sensitivity of intraoperative frozen section diagnosis of the sentinel node in melanoma and breast cancer patients was determined, and the results showed that the sensitivity was 47% and 74% respectively.
Journal ArticleDOI
Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.
Danielle Lienard,A. M. M. Eggermont,Heimen Schraffordt Koops,Bin B. R. Kroon,G Towse,S Hiemstra,P Schmitz,J Clarke,G. Steinmann,Rosenkaimer F,Ferdy J. Lejeune +10 more
TL;DR: The data suggest that TNFalpha associated with melphalan may be superior tomelphalan alone for ILP, and the median survival time estimated by the Kaplan-Meier method was 819 days.